Zimmer Biomet Holdings Inc (ZBH) : Paradigm Asset Management Co scooped up 44,349 additional shares in Zimmer Biomet Holdings Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 45,550 shares of Zimmer Biomet Holdings Inc which is valued at $5,891,437.Zimmer Biomet Holdings Inc makes up approximately 1.01% of Paradigm Asset Management Co’s portfolio.
Other Hedge Funds, Including , 1832 Asset Management sold out all of its stake in ZBH during the most recent quarter. The investment firm sold 160,588 shares of ZBH which is valued $20,770,452.Thompson Davis boosted its stake in ZBH in the latest quarter, The investment management firm added 462 additional shares and now holds a total of 487 shares of Zimmer Biomet Holdings Inc which is valued at $64,118. Zimmer Biomet Holdings Inc makes up approx 0.10% of Thompson Davis’s portfolio.Ftb Advisors reduced its stake in ZBH by selling 248 shares or 12.71% in the most recent quarter. The Hedge Fund company now holds 1,703 shares of ZBH which is valued at $223,331. Zimmer Biomet Holdings Inc makes up approx 0.03% of Ftb Advisors’s portfolio.Regentatlantic Capital reduced its stake in ZBH by selling 225 shares or 1.78% in the most recent quarter. The Hedge Fund company now holds 12,434 shares of ZBH which is valued at $1,572,777. Zimmer Biomet Holdings Inc makes up approx 0.15% of Regentatlantic Capital’s portfolio.
Zimmer Biomet Holdings Inc opened for trading at $129.71 and hit $130.96 on the upside on Monday, eventually ending the session at $130.59, with a gain of 0.83% or 1.08 points. The heightened volatility saw the trading volume jump to 8,56,928 shares. Company has a market cap of $26,120 M.
On the company’s financial health, Zimmer Biomet Holdings Inc reported $2.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.97. The company had revenue of $1934.00 million for the quarter, compared to analysts expectations of $1898.18 million. The company’s revenue was up 65.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.58 EPS.
Many Wall Street Analysts have commented on Zimmer Biomet Holdings Inc. SunTrust Initiated Zimmer Biomet Holdings Inc on Aug 11, 2016 to “Buy”, Price Target of the shares are set at $155.Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 150 from a previous price target of $143 .Company shares were Reiterated by Needham on Jul 18, 2016 to “Buy”, Firm has raised the Price Target to $ 143 from a previous price target of $134 .
Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.